Atlas Trials

Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System Lymphoma

Clinical trial NCT05334238 · UNKNOWN

Trial details

NCT number
NCT05334238
Sponsor
Ruijin Hospital
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
Primary Central Nervous System Lymphoma
Start date
2021-12-01
Primary completion
2024-05-30
Enrollment
174

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.